Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

veludacigib

An orally bioavailable inhibitor of diacylglycerol kinase zeta (DGKzeta), with potential antineoplastic activity. Upon oral administration, veludacigib inhibits the activity of DGKzeta. This prevents the phosphorylation of diacylglycerol (DAG) to phosphatidic acid (PA), and modulates the DAGzeta-regulated cellular signaling pathways. This may inhibit the proliferation of tumor cells in which DGKzeta is overactivated. DGKzeta is overexpressed in certain cancer cells and plays an important role in tumor cell survival. DAGzeta may also play a key role in tumor immunosuppression.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:DGKZ inhibitor BAY2965501
DGKzeta inhibitor BAY2965501
DGKzi BAY2965501
diacylglycerol kinase zeta inhibitor BAY2965501
Code name:BAY 2965501
BAY-2965501
BAY2965501
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search